Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis

Hemodialysis International

Volumn 13, Issue 4, 2009, Pages 460-466

  Brown, Michaela C ^a   Gaffney, Dairena ^b   Gemmell, Clare ^a   Oakes, Eleanor ^b   Morris, Scott ^a   Spooner, Richard ^b   Jardine, Alan G ^a   Geddes, Colin C ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

Author keywords

Anemia; Erythropoietin; Hemochromatosis; Hemodialysis; HFE gene; Iron

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HFE PROTEIN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ERYTHROPOIESIS; FEMALE; GENE MUTATION; HEMOCHROMATOSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MUTATIONAL ANALYSIS; TREATMENT DURATION;

ANEMIA; FEMALE; GENOTYPE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; RENAL DIALYSIS;

EID: 70350557339     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00378.x     Document Type: Article

References (28)

1. Fishbane S, Mishaka JK. Iron management in end-stage renal disease (Review). Am J Kidney Dis 1997, 29:319-333.
2. Chiang WS, Trinda D, Olynk JK. Iron overload (Review). Clin Chim Acta 2005, 358:24-36.
3. Feder JN, Gnirke A, Thomas W. A novel MHC Class I like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13:399-408.
4. Bomford A. Genetics of haemochromatosis. Lancet 2002, 360:1673-1681.
5. Beutler E, Gelbart T, West C. Mutation analysis of the HFE gene in Brazilian populations. Blood Cells Mol Dis 1996, 22:187-194.
6. Jazwinska EC, Cullan LM, Busfield F. Haemochromatosis and HLA-H. Nat Genet 1996, 14:249-251.
7. Jouanolle AM, Gandon G, Jezequel P. Haemochromatosis and HLA-H. Nat Genet 1996, 14:251-252.
8. Roberts AG, Whatley SD, Morgan RR. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997, 349:321-323.
9. Bulaj ZJ, Griffen LM, Jorde LB. Clinical and biochemical abnormalities in people heterozygous for haemochromatosis. N Engl J Med 1996, 335:1799-1805.
10. Van Aken MO, de Craen AJM, Gussekloo J. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old. Eur J Invest 2002, 32:750-754.
11. Campbell S, George DK, Robb S. The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease. Heart 2003, 89:1023-1026.
12. Thorburn D, Curry G, Spooner R. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002, 50:248-252.
13. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?. Nephrology (Carlton) 2004, 9:223-228.
14. http://www.renal.org/guidelines/module2.html, Renal Association Guideline 2: Complications of CKD, 4th ed, 2007 Available from, (accessed date: June 2007)
15. Canavese C, Bergamo D, Barbieri S. Clinical relevance of hemochromatosis-related HFE C282Y/H63D gene mutations in patients on chronic dialysis. Clin Nephrol 2002, 58:438-444.
16. Martins R, Picanco I, Fonseca A. The role of HFE mutations on iron metabolism in beta-thalassemia carriers. J Hum Genet 2004, 49:651-655.
17. Melis MA, Cau M, Deidda FA. H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers. Haematologica 2002, 87:242-245.
18. Borgnapignatti C, Solinas A, Bombieri C. The haemochromatosis mutations do not modify the clinical picture of thalassaemia major in patients regularly transfused and chelated. Br J Haematol 1998, 103:813-816.
19. Nicolas G, Bennoun M, Porteu A. Severe iron deficiency in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002, 99:4596-4601.
20. Laftah AH, Ramesh B, Simpson RJ. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004, 103:3940-3944.
21. Petrangelo P. Haemochromatosis. Hepatology 2007, 46:1291-1301.
22. Arnold J, Sangwiya A, Bhatkal B, Arnold A. Defective release of hepcidin not defective synthesis is the primary pathogenic mechanism in HFE-haemochromatosis. Med Hypothesis 2008, 70:1197-1200.
23. Malyszko J, Malyszko J, Pawlak K. Hepcidin, iron status and renal function in chronic renal failure, kidney transplantation and haemodialysis. Am J Haematol 2006, 81:832-837.
24. Kulaksiz H, Gehrke SG, Janetsko A. Pro-hepcidin. Gut 2004, 53:735-745.
25. Hamada Y, Kono T-N, Moriguchi Y, Higuchi M, Fukagawa M. Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats. Nephrol Dial Transplant 2008, 23:1886-1891.
26. Chen YC, Hung SC, Tarng DC. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am J Kidney Dis 2006, 47:1036-1044.
27. Beard JL, Murray-Kolb LE, Rosales FJ. Interpretation of serum ferritin concentrations as indicators of total-body iron stores in survey populations. Am J Clin Nutr 2006, 84:1498-1505.
28. Brugnara C, Chambers LA, Malynn E. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin. Blood 1993, 82:956-964.